Hostname: page-component-848d4c4894-pftt2 Total loading time: 0 Render date: 2024-05-13T15:24:33.834Z Has data issue: false hasContentIssue false

FC01.01 - Impact of audit and feedback on antipsychotic prescribing in schizophrenia

Published online by Cambridge University Press:  16 April 2020

A.J. Wheeler
Affiliation:
CRRC, Waitemata DHB, Auckland, New Zealand
V. Humberstone
Affiliation:
Adult Mental Health Services, Counties Manukau DHB, Auckland, New Zealand
E. Robinson
Affiliation:
Section of Epidemiology and Biostatistics, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
J. Sheridan
Affiliation:
School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
P. Joyce
Affiliation:
Department of Psychological Medicine, University of Otago, Christchurch, New Zealand

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

Examine impact of audit and feedback on antipsychotic prescribing in schizophrenia over 4.5-years.

Methods:

Clinical files in three outpatient psychiatric services in Auckland, New Zealand were reviewed at two time-points (March-2000;October-2004). After the first audit, feedback was provided to all three services. Baseline prescribing variations between services were found for antipsychotic combinations and atypical prescribing, in particular clozapine. In two services audit and feedback continued with two interim reviews (October-2001;March-2003). Specific feedback and interventions targeting clozapine use were introduced in both services. No further audit or feedback occurred in the third service until the final audit. Data were collected (patient characteristics, diagnosis, antipsychotic treatment) and analysed at each audit.

Results:

Three prescribing variables (antipsychotic monotherapy, atypical and clozapine use) were consistent with practice recommendations at the final audit (85.7%, 82.7% and 34.5% respectively) and had changed in the desired direction for all three services over 4.5-years. At baseline there were differences between the three services. One service had baseline prescribing variables closest to recommendations, was actively involved in audit, and improved further. The second service, also actively involved in audit had baseline prescribing variables further from recommendations but improved the most. The service not involved in continuing audit and feedback made smaller changes, and atypical and clozapine use at endpoint were significantly lower despite at baseline being comparable to the service which improved the most.

Conclusions:

We found high intensity audit and feedback was an effective intervention in closing the gap between recommended and clinical practice for antipsychotic prescribing.

Type
Free Communications
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.